Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Glycotope GmbH
BioCentury | Jan 22, 2025
Deals
Simcere snaps up rights to Fermion’s analgesic, a potential Lilly competitor
BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope
BioCentury | Jul 8, 2024
Deals
Deals report: Lilly acquires Morphic, GSK gets full rights for mRNA vaccines from CureVac
Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope
BioCentury | Mar 25, 2022
Management Tracks
Emergent appoints Harsanyi, Katkin in board restructuring
Plus Sosei ratifies executive changes and updates from Mesoblast, Creyon and more
BioCentury | Jan 23, 2021
Emerging Company Profile
ONK’s CAR NK cells hit the TRAIL
Emerging Company Profile: Ireland’s ONK Therapeutics soups up CAR NK cells with TRAIL variants
BioCentury | Aug 8, 2020
Management Tracks
PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more
Items per page:
1 - 10 of 23